Pipeline
Our clinical and preclinical pipeline includes wholly owned and partnered therapeutic candidates targeting difficult-to-treat cancers and other serious diseases.
Product Candidate
Preclinical
Phase 1
Phase 2
Pivotal
Partner
Zanidatamab
Zanidatamab
HER2 x HER2 Bispecific Antibody
Zanidatamab is an investigational bispecific antibody (developed using Zymeworks proprietary Azymetric™ platform) that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. This unique design and increased binding results in multiple mechanisms of action, including dual HER2 signal blockade, removal of HER2 protein from the cell surface, and immune-mediated cytotoxicity leading to encouraging antitumor activity in patients. Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is being developed by Jazz Pharmaceuticals Ltd. and BeiGene, Ltd. under license agreements from Zymeworks.
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for zanidatamab development in patients with previously treated HER2 gene-amplified biliary tract cancers (BTC), and two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard of care chemotherapy for first-line gastroesophageal adenocarcinoma (GEA).
Additionally, zanidatamab has received Orphan Drug designations from FDA for the treatment of BTC and GEA, as well as Orphan Drug designation from the European Medicines Agency for the treatment of BTC and gastric cancer.
Zanidatamab was also granted Breakthrough Therapy designation from the Center for Drug Evaluation (CDE) in China.
Product Status
Indications
- Biliary Tract Cancers
- Breast Cancer
- Gastroesophageal Adenocarcinomas
- Colorectal Cancer
- HER2-Expressing Cancers
Partner
Technology
Product Candidate
1st-Line Gastroesophageal Adenocarcinomas
Phase: Pivotal
Partner:
Product Candidate
2nd-Line Biliary Tract Cancers
Phase: Pivotal
Partner:
Product Candidate
1st-Line Gastrointestinal Cancers
Phase: Pivotal
Partner:
Product Candidate
Late-Line Breast Cancer
Phase: Phase 2
Partner:
Product Candidate
HER2-Expressing Cancers
Phase: Preclinical
Partner:
Zanidatamab Zovodotin
Zanidatamab Zovodotin
HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC)
Zanidatamab zovodotin (ZW49) is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ Auristatin platforms technologies. Zanidatamab zovodotin combines the unique design of zanidatamab with the addition of a toxic chemotherapy that we developed in-house. Zanidatamab zovodotin delivers a novel auristatin (cell-killing compound) to tumor cells via a cleavable linker by taking advantage of the enhanced ability of its antibody (zanidatamab) to internalize into the tumor cell. In addition to its cytotoxic properties zanidatamab zovodotin’s unique design promotes immunogenic cell death.
Zanidatamab zovodotin, in combination with a checkpoint inhibitor, is planned to be evaluated in a Phase 2 trial in patients with HER2-overexpressing non-small cell lung cancer.
Product Status
Indications
- HER2-Expressing Cancers
Technology
Preclinical
Product Candidate
ZW191
Phase: Preclinical
ZW191
Folate Receptor-⍺ Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
ZW191 is an antibody-drug conjugate that is engineered to target a protein called folate receptor-⍺ (FR⍺) found on the surface of a variety of tumors such as on ovarian, endometrial, and lung cancers. ZW191’s differentiated design increases its ability to internalize into FR⍺ -expressing cells. Further, it releases a toxic chemotherapy that we developed in-house, a bystander active topoisomerase-1 inhibitor (ZD06519), to kill tumor cells.
With promising preclinical tolerability and anti-tumor activity, ZW191 is currently in the Investigational New Drug (IND)-enabling stage of development and is projected to enter Phase I clinical trials in 2024.
Product Status
Indications
- Ovarian cancer & gynaecological cancers
- Non-small cell lung cancer
Technology
Product Candidate
ZW171
Phase: Preclinical
ZW171
2+1 MSLN x CD3 Bispecific Antibody
ZW171 is a bispecific antibody that is designed to engage two different types of cells, tumor cells and immune cells (T cells). ZW171 binds to the tumor target mesothelin (MSLN), which is expressed on many different tumors including pancreatic, colorectal and ovarian cancer cells, as well as targeting CD3 receptors on T cells to redirect T cell activity towards the tumor to enable T cell-mediated tumor cell killing. This T cell engager differs by its tumor selective binding to spare normal tissues and improve anti-tumor activity and tolerability. Our team engineered and optimized the antibody design using our Azymetric™ and EFECT™ technologies.
With promising preclinical tolerability and anti-tumor activity, ZW171 is currently in the IND-enabling stage of development and is projected to enter Phase I clinical trials in 2024.
Product Status
Indications
- Ovarian cancer
- Non-small cell lung cancer
- Other mesothelin-expressing cancers
Technology
Product Candidate
ZW251
Phase: Preclinical
ZW251
Glypican-3 Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
ZW251 is the first antibody-drug conjugate engineered to target a protein called glypican-3 (GPC3), which is found on a difficult-to-treat liver cancer, hepatocellular carcinoma (HCC). The antibody is uniquely designed to target and strongly bind to the GPC3 protein, then release a toxic chemotherapy that we developed in-house, a bystander active topoisomerase-1 inhibitor (ZD06519), to kill the tumor cells.
With promising preclinical tolerability and anti-tumor activity, ZW251 is currently in the IND enabling stage of development and is projected to enter Phase I clinical trials in 2025.
Product Status
Indications
Hepatocellular carcinoma (HCC)
Technology
Product Candidate
ZW220
Phase: Preclinical
ZW220
NaPi2b Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate
ZW220 is an antibody-drug conjugate that is engineered to target a protein called sodium-dependent phosphate transporter 2b (NaPi2b) found on the surface of a variety of tumors, such as on ovarian, lung and pancreatic cancers. ZW220 differentiated design optimizes its ability to target and strongly bind to the NaPi2b protein and then effectively internalize into the cell. ZW220 releases a toxic chemotherapy that we developed in-house, a bystander active topoisomerase-1 inhibitor (ZD06519), to kill tumor cells.
With promising preclinical tolerability and anti-tumor activity, ZW220 is currently in the IND- enabling stage of development and is projected to enter Phase I clinical trials in 2025.
Product Status
Indications
- Ovarian cancer
- Non-small cell lung cancer
Technology
Partners
Product Candidate
XB002 Tissue Factor ADC
Phase: Phase 1
Partner:
XB002 Tissue Factor ADC
Product Status
Indications
- Solid Tumors
Partner
Technology
Product Candidate
JNJ-78278343
Phase: Phase 1
Partner:
JNJ-78278343
(CD3 x KLK2)
Product Status
Indications
- Castration-Resistant Prostate Cancer
Partner
Technology
Product Candidate
Bispecific
Phase: Pre-clinical
Partner:
Product Candidate
Bispecific
Phase: Pre-clinical
Partner:
Bispecific
Product Status
Indications
- Immuno-Oncology
Partner
Technology
Product Candidate
Bispecific
Phase: Pre-clinical
Partner: